HEPA: Hepion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on HEPA: Hepion Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.54
Enterprise Value ($M) 7.95
Book Value ($M) -1.86
Book Value / Share -0.17
Price / Book -1.90
NCAV ($M) -1.86
NCAV / Share -0.17
Price / NCAV -1.90

Profitability (mra)
Return on Invested Capital (ROIC) -11.43
Return on Assets (ROA) -0.83
Return on Equity (ROE) -1.75

Liquidity (mrq)
Quick Ratio 0.51
Current Ratio 0.51

Balance Sheet (mrq) ($M)
Current Assets 1.61
Assets 1.61
Liabilities 3.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -19.35
Net Income -13.19
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -18.22
Cash from Investing -0.60
Cash from Financing 4.35

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-24 13G Bigger Capital Fund L P 9.99
11-14 13G/A Armistice Capital, Llc 4.99 -27.14

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O
2025-01-13 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-06-25 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A
2024-05-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 o TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 310,277 979,388 31.68
2025-04-16 255,030 924,453 27.59
2025-04-15 178,739 1,066,651 16.76

(click for more detail)

Similar Companies
GTBP – GT Biopharma, Inc. GYRE – Gyre Therapeutics, Inc.
HCWB – HCW Biologics Inc. HOOK – HOOKIPA Pharma Inc.
HOTH – Hoth Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io